Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apabetalone + dapagliflozin
- Development stage
- Phase 3
- Lead developer
- ResVerlogiX
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Apabetalone + dapagliflozin is a combination of two small molecule drugs: apabetalone, a selective bromodomain and extraterminal domain (BET) inhibitor targeting bromodomain 2 (BD2) and modulating gene expression to impact inflammation and other processes involved in cardiovascular disease; and dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor that lowers blood glucose by preventing renal glucose reabsorption. The combination is under clinical investigation primarily for reducing major adverse cardiovascular events (MACE) and heart failure in patients with type 2 diabetes and cardiovascular disease, based on evidence of synergistic cardioprotective effects compared to either agent alone[1][3][5][7].
02
Targets
BRD2 BD2 (Bromodomain-containing protein 2, bromodomain 2)BRD3 BD2 (Bromodomain-containing protein 3 (BRD3) bromodomain 2 (BD2))Bromodomain-containing protein 4, Bromodomain 2SGLT2 (Sodium-glucose cotransporter protein subunit 2)BRD2 (Bromodomain-containing protein 2)
Beyond the preview
Go deeper on apabetalone + dapagliflozin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apabetalone + dapagliflozin.